- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06330584
Administration of Intranasal Midazolam for Anxiety in Palliative Care (AIM Care)
Administration of Intranasal Midazolam for Anxiety in Palliative Care - a Double-blind, Randomized, Placebo-controlled Multicenter Exploratory Pilot Study With a Nested Pharmacokinetic Analysis
Study Overview
Status
Conditions
Detailed Description
30 patients (10 patients per study arm) will be enrolled. All patients hospitalized at the three study sites, which are prescribed intranasal midazolam in their as-needed drug regimen and who meet inclusion criteria, are eligible. Patients will be asked for consent at the time of prescription of midazolam by the attending physician. Patients who have provided consent and have been randomized to one of the arms will be included (block randomization).
In a nested analysis, pharmacokinetic properties of all three doses will be analyzed in participants with available venous access.
The primary outcome is the change in patient-reported levels of anxiety. Secondary outcomes include time until first requested additional dose, cumulative number of doses including time points of administration after the first application, oxygen saturation, heart rate, cortisol levels in oral fluid, levels of sedation on the Richmond Agitation Sedation Scale Palliative Version (RASS-PAL), and occurrence of adverse drug events.
The primary and secondary outcomes will be assessed at baseline, i.e., immediately before the intervention (0 minutes) and 30 minutes after the intervention. Two of the secondary outcomes ('Time to first requested additional dose' and 'Cumulative number of doses over 24 hours') will be assessed starting 30 minutes after the intervention up to 24 hours after the intervention.
In patients included in the nested pharmacokinetic analysis, basic pharmacokinetic parameters will additionally be assessed at 10 time points, starting at baseline (0 minutes) up to 240 minutes after the intervention.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Manuel Haschke, MD
- Phone Number: +41 (0)31 632 67 93
- Email: manuel.haschke@insel.ch
Study Contact Backup
- Name: Ursina Wernli, MSc
- Email: ursina.wernli@students.unibe.ch
Study Locations
-
-
-
Bern, Switzerland, 3010
- Inselspital, Universitätsspital Bern
-
Contact:
- Manuel Haschke, MD
- Phone Number: +41 (0)31 632 67 93
- Email: manuel.haschke@insel.ch
-
Principal Investigator:
- Manuel Haschke
-
Bern, Switzerland
- Universitäres Zentrum für Palliative Care (UZP)
-
Contact:
- Steffen Eychmüller, MD
- Phone Number: +41 (0)31 632 51 07
- Email: steffen.eychmueller@insel.ch
-
Zürich, Switzerland, 8037
- Zentrum für Palliative Care, Stadtspital Zürich
-
Contact:
- Andreas Major, MD
- Phone Number: +41 (0)44 417 29 26
- Email: andreas.major@stadtspital.ch
-
Zürich, Switzerland, 8091
- Kompetenzzentrum Palliative Care, Universitätsspital Zürich
-
Contact:
- Caroline Hertler, MD
- Phone Number: +41 (0)44 255 29 34
- Email: caroline.hertler@usz.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult palliative care patients (≥ 18 years) hospitalized at one of the study sites
- Self-reported acute anxiety with clinical indication for intranasal midazolam administration according to attending physician
- Patient willing and able to provide written informed consent
- Informed consent as documented by signature
- Patient willing and able to complete anxiety assessment
- Additionally for nested pharmacokinetic analysis: Patients with available central or peripheral venous access, i.e., peripheral venous catheter (PVC), central venous catheter (CVC), peripherally inserted central venous catheter (PICC) line, midline catheter, or PORT-A-CATH® (PAC), and patient willing and able to provide blood samples
Exclusion Criteria:
- Intranasal midazolam prescribed for seizures
- midazolam (any route of administration) prescribed and administered for continuous sedation
- History of allergy or hypersensitivity to midazolam
- History of benzodiazepine-related paradoxical reaction to midazolam
- Impaired nasal absorption (e.g., nasogastric tube, nasal obstruction, nasal polyps, etc.)
- Intranasal midazolam within 24 h before study enrollment
- Time between informed general consent for study participation through investigators and planned midazolam administration < 24 h
- Co-medication with strong CYP3A4 inducers or inhibitors according to pre-defined list
- Intake of grapefruit or its juice
- Inability to follow the procedures of the study (i.e., provision of Informed Consent, completion of assessment tool, e.g., due to language problems or dementia)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Total dose of midazolam = 0 mg (no active compound)
|
A unit-dose nasal spray will be used for the intervention. 1 spray (= 0.1 μl = 0 mg midazolam/spray) in each nostril, i.e., no active compound |
Active Comparator: Standard of Care (SOC)
Total dose of midazolam = 0.9 mg
|
A unit-dose nasal spray will be used for the intervention. 1 spray (= 0.1 μl = 0.45 mg midazolam/spray) in each nostril, i.e., total dose of midazolam 0.9 mg |
Active Comparator: Double Dose of Standard of Care (2xSOC)
Total dose of midazolam = 1.8 mg
|
A unit-dose nasal spray will be used for the intervention. 1 spray (= 0.1 μl = 0.9 mg midazolam/spray) in each nostril, i.e., total dose of midazolam 1.8 mg |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in anxiety levels, measured by Visual Analogue Scale (VAS)
Time Frame: t [0 minutes, 30 minutes]
|
Patient-reported levels of anxiety, measured by VAS (0-100 mm, from left 'no anxiety at all' to right 'worst possible anxiety') at baseline (0 minutes) and 30 minutes after study drug or placebo administration.
|
t [0 minutes, 30 minutes]
|
Change from baseline in anxiety levels, measured by Numerical Rating Scale (NRS)
Time Frame: t [0 minutes, 30 minutes]
|
Patient-reported levels of anxiety, measured by NRS (0-10, 0 = 'no anxiety at all' to 10 = 'worst possible anxiety') at baseline (0 minutes) and 30 minutes after study drug or placebo administration.
|
t [0 minutes, 30 minutes]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sedation
Time Frame: t [0 minutes, 30 minutes]
|
Richmond Agitation Sedation Scale Palliative Version (RASS-PAL) The RASS-PAL ranges from +4 (combative) to -5 (not rousable), where a higher score (below 0) is associated with agitation and a lower score (below 0) is associated with sedation. A score of 0 (alert and calm) is considered the most balanced state. |
t [0 minutes, 30 minutes]
|
Oxygen saturation SaO2 (percent %)
Time Frame: t [0 minutes, 30 minutes]
|
Oxygen saturation
|
t [0 minutes, 30 minutes]
|
Heart rate (bpm)
Time Frame: t [0 minutes, 30 minutes]
|
t [0 minutes, 30 minutes]
|
|
Cortisol levels in oral fluid
Time Frame: t [0 minutes, 30 minutes]
|
t [0 minutes, 30 minutes]
|
|
Time to first requested additional dose
Time Frame: t [starting assessment 30 minutes after intervention up to 24 hours after intervention]
|
30 minutes after the intervention, additional doses may be administered as-needed.
The time point until the first additional dose starting 30 minutes after the intervention is assessed.
The time point can occur anywhere between 30 minutes and 24 hours after the intervention.
|
t [starting assessment 30 minutes after intervention up to 24 hours after intervention]
|
Cumulative number of doses over 24 hours
Time Frame: t [starting assessment 30 minutes after intervention up to 24 hours after intervention]
|
As additional doses may be administered after 30 minutes after the intervention, every additional requested dose is assessed and the total number of doses over 24 hours after the intervention is calculated.
|
t [starting assessment 30 minutes after intervention up to 24 hours after intervention]
|
Number of patients with adverse drug events (ADEs)
Time Frame: t [starting assessment 30 minutes after intervention up to 24 hours after intervention]
|
t [starting assessment 30 minutes after intervention up to 24 hours after intervention]
|
|
Peak plasma concentration (Cmax)
Time Frame: t [0 minutes up to 240 minutes after intervention]
|
Pharmacokinetic parameter obtained by non-compartmental analysis (NCA) or compartmental analysis (CA) in a pre-defined eligible subset of patients (i.e., patients with a central or peripheral venous access). There will be 10 measurement points: at baseline (0 minutes, i.e., before intervention) and at t [2.5, 5, 10, 15, 30, 60, 120, 180, 240 minutes]. |
t [0 minutes up to 240 minutes after intervention]
|
Time to reach the peak plasma concentration (Tmax)
Time Frame: t [0 minutes up to 240 minutes after intervention]
|
Pharmacokinetic parameter obtained by non-compartmental analysis (NCA) or compartmental analysis (CA) in a pre-defined eligible subset of patients (i.e., patients with a central or peripheral venous access). There will be 10 measurement points: at baseline (0 minutes, i.e., before intervention) and at t [2.5, 5, 10, 15, 30, 60, 120, 180, 240 minutes]. |
t [0 minutes up to 240 minutes after intervention]
|
Elimination half-life (t1/2)
Time Frame: t [0 minutes up to 240 minutes after intervention]
|
Pharmacokinetic parameter obtained by non-compartmental analysis (NCA) or compartmental analysis (CA) in a pre-defined eligible subset of patients (i.e., patients with a central or peripheral venous access). There will be 10 measurement points: at baseline (0 minutes, i.e., before intervention) and at t [2.5, 5, 10, 15, 30, 60, 120, 180, 240 minutes]. |
t [0 minutes up to 240 minutes after intervention]
|
Area under the curve (AUC0-Τ, AUC0-∞)
Time Frame: t [0 minutes up to 240 minutes after intervention]
|
Pharmacokinetic parameter obtained by non-compartmental analysis (NCA) or compartmental analysis (CA) in a pre-defined eligible subset of patients (i.e., patients with a central or peripheral venous access). There will be 10 measurement points: at baseline (0 minutes, i.e., before intervention) and at t [2.5, 5, 10, 15, 30, 60, 120, 180, 240 minutes]. |
t [0 minutes up to 240 minutes after intervention]
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Carla Meyer-Massetti, PhD, Inselspital, Universitätsspital Bern
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Anxiety Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Midazolam
Other Study ID Numbers
- AIM Care Study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
Clinical Trials on Placebo Nasal Spray 0 mg/spray
-
Oyster Point Pharma, Inc.CompletedDry Eye DiseaseUnited States
-
VistaGen Therapeutics, Inc.TerminatedSocial Anxiety DisorderUnited States
-
NPO PetrovaxCompletedAcute Respiratory InfectionRussian Federation
-
University of ChicagoMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Withdrawn
-
VistaGen Therapeutics, Inc.RecruitingSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.CompletedSocial Anxiety DisorderUnited States
-
Sara EspinozaThe University of Texas Health Science Center, Houston; The University of Texas... and other collaboratorsCompletedObesity | Sedentary Lifestyle | Sarcopenia | Aging | Sarcopenic ObesityUnited States
-
Chulalongkorn UniversityNot yet recruiting
-
Viiral Nordic ABCompleted
-
University Hospital, AntwerpUnknownChronic Rhinosinusitis (Diagnosis) | Probiotics | Healthy Volunteers | Nasal Disease | SpraysBelgium